Navigation Links
New Polio Vaccine Shows Major Advantages: Study
Date:10/26/2010

TUESDAY, Oct. 26 (HealthDay News) -- A new bivalent oral vaccine that targets two deadly strains of polio -- types 1 and 3 -- triggers a stronger immune response than the existing trivalent vaccine and an immune response that's similar to monovalent vaccines, a new study shows.

Use of trivalent and monovalent vaccines has reduced the number of countries where polio is endemic from more than 125 in 1988 to just four today. Transmission of polio virus types 1 and 3 persists in parts of Afghanistan, Pakistan, India and Nigeria.

The bivalent oral vaccine is already widely used in efforts to halt transmission of polio virus types 1 and 3, but this study set out to examine whether it triggers as much immunity as the other vaccines.

Between August and December 2008, researchers gave 830 newborns in India either the monovalent, bivalent or trivalent vaccines in two doses, including one at birth and one 30 days later. Antibody levels were measured in blood samples before vaccination and after the first and second doses of the vaccines.

Overall, the immune response induced by the bivalent vaccine was significantly higher than the trivalent vaccine and similar to the monovalent vaccine, the investigators found.

The study was released online Oct. 25 in advance of publication in an upcoming print issue of The Lancet.

"The major advantages of the bivalent vaccine ... is that it will enhance individual and population immunity simultaneously for both poliovirus types 1 and 3, without any serious loss in immunogenicity compared with the [monovalent vaccines]," the researchers said in a news release from the publisher.

More information

The American Academy of Family Physicians has more about polio vaccine.

-- Robert Preidt

SOURCE: The Lancet, news release, Oct. 25, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Rotary International and I Imagine Studio Have Teamed up to Helps Kick Polio out of Africa
2. Polio outbreak in Tajikistan is cause for alarm
3. Vaccine May Prevent TB in People With HIV
4. Vaccine Not Fail-Safe in Ongoing Mumps Outbreak
5. New strategy produces promising advance in cancer vaccines
6. Screens, Vaccine for HPV Less Beneficial in Older Women
7. New Technology Could Widen Reach of Vaccines
8. Texas-based consortium announces groundbreaking vaccine research program
9. The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies Failure to Provide Adequate Safety Research
10. Possible vaccine for mesothelioma proven safe
11. Groundbreaking research to find vaccine for hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Polio Vaccine Shows Major Advantages: Study
(Date:12/7/2016)... IL (PRWEB) , ... December 07, 2016 , ... AlignLife ... season. Many children are not fortunate enough to receive bountiful gifts wrapped tightly ... unwrapping presents can bring to the children of the world. , In exchange for ...
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 ... ... A new study entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” ... dogs. The study was published in the prestigious Journal of Veterinary Science & ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... that its fully redesigned website, which launched October 17, 2016, features comprehensive information ... design and easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser ... Holiday Party Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through ... Phoenix Valley with Delightful Deals on Botox® and Juvederm® just in time ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 Media’s ... in the Folio: Marketing Awards competition. Live From won in the Use of ... inventive, and ultimately successful projects undertaken by the media industry’s most innovative marketing ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- According to responses from U.S. oncologists that participated in ... with non-small cell lung cancer (NSCLC), treatment decisions are made ... status. The findings of the survey were presented today as ... ) at the 2016 World Conference on Lung Cancer (WCLC) ... survey results revealed an overall high rate of EGFR mutation ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 ... II trial in patients with unresectable malignant pleural ... survival (PFS). The data, presented at the 17 ... in Vienna , showed nintedanib ... to placebo plus pemetrexed/cisplatin, with a significantly improved ...
(Date:12/7/2016)... YORK , December 7, 2016 ... Pharmaceuticals PLC (NASDAQ: JAZZ ), Anthera Pharmaceuticals Inc. ... DNAI ), and AveXis Inc. (NASDAQ: AVXS ... Sector Index fell roughly 37% to reach a level equal ... it is down by approximately 14% for the year, it ...
Breaking Medicine Technology: